Pure Global

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD - Trial NCT06345404

Access comprehensive clinical trial information for NCT06345404 through Pure Global AI's free database. This Phase 1 trial is sponsored by Corvus Pharmaceuticals, Inc. and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06345404
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06345404
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis

Study Focus

Atopic Dermatitis

Soquelitinib

Interventional

drug

Sponsor & Location

Corvus Pharmaceuticals, Inc.

Burlingame, United States of America

Timeline & Enrollment

Phase 1

Apr 01, 2024

Apr 01, 2025

64 participants

Primary Outcome

Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms

Summary

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate
 to severe AD

ICD-10 Classifications

Atopic dermatitis
Atopic dermatitis, unspecified
Other atopic dermatitis
Acute atopic conjunctivitis
Allergic contact dermatitis

Data Source

ClinicalTrials.gov

NCT06345404

Non-Device Trial